G Curigliano, H J Burstein, E P Winer, M Gnant, P Dubsky, S Loibl, M Colleoni, M M Regan, M Piccart-Gebhart, H-J Senn, B Thürlimann, F André, J Baselga, J Bergh, H Bonnefoi, S Y Brucker, F Cardoso, L Carey, E Ciruelos, J Cuzick, C Denkert, A Di Leo, B Ejlertsen, P Francis, V Galimberti, J Garber, B Gulluoglu, P Goodwin, N Harbeck, D F Hayes, C-S Huang, J Huober, K Hussein, J Jassem, Z Jiang, P Karlsson, M Morrow, R Orecchia, K C Osborne, O Pagani, A H Partridge, K Pritchard, J Ro, E J T Rutgers, F Sedlmayer, V Semiglazov, Z Shao, I Smith, M Toi, A Tutt, G Viale, T Watanabe, T J Whelan, B Xu
The 15th St. Gallen International Breast Cancer Conference 2017 in Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies for early breast cancer. Treatments were assessed in light of their intensity, duration and side-effects, seeking where appropriate to escalate or de-escalate therapies based on likely benefits as predicted by tumor stage and tumor biology. The Panel favored several interventions that may reduce surgical morbidity, including acceptance of 2 mm margins for DCIS, the resection of residual cancer (but not baseline extent of cancer) in women undergoing neoadjuvant therapy, acceptance of sentinel node biopsy following neoadjuvant treatment of many patients, and the preference for neoadjuvant therapy in HER2 positive and triple-negative, stage II and III breast cancer...
August 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology